Next-generation therapies for pancreatic cancer Review
| Authors: | Buckley, C. W.; O’Reilly, E. M. |
| Review Title: | Next-generation therapies for pancreatic cancer |
| Abstract: | Introduction: Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC (mPDAC) is cytotoxic chemotherapy. NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, oxaliplatin) is an emerging standard of care in the metastatic setting. An evolving understanding of PDAC pathogenesis is driving a shift toward targeted therapy. Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, has regulatory approval for maintenance therapy in BRCA-mutated mPDAC along with other targeted agents receiving disease-agnostic approvals including for PDAC with rare fusions and mismatch repair deficiency. Ongoing research continues to identify and evaluate an expanding array of targeted therapies for PDAC. Areas covered: This review provides a brief overview of standard therapies for PDAC and an emphasis on current and emerging targeted therapies. Expert opinion: There is notable potential for targeted therapies for KRAS-mutated PDAC with opportunity for meaningful benefit for a sizable portion of patients with this disease. Further, emerging approaches are focused on novel immune, tumor microenvironment, and synthetic lethality strategies. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | treatment response; gene mutation; overall survival; somatic mutation; genetics; review; cisplatin; erlotinib; fluorouracil; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; pancreas cancer; pancreatic neoplasms; neurotoxicity; antineoplastic agent; colorectal cancer; cell proliferation; dna damage; gene; ipilimumab; cancer immunotherapy; progression free survival; microrna; gene expression; epidermal growth factor receptor; carcinoma, pancreatic ductal; small interfering rna; maintenance therapy; rna interference; cyclophosphamide; antineoplastic activity; cytotoxicity; cancer therapy; irinotecan; tumor suppressor gene; karnofsky performance status; minimal residual disease; folinic acid; mismatch repair; pancreas tumor; cell migration; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; targeted therapy; pancreatic adenocarcinoma; kras; oxaliplatin; brca; mesothelin; olaparib; programmed death 1 ligand 1; programmed death 1 receptor; non small cell lung cancer; transcription factor gata 6; tumor microenvironment; randomized controlled trial (topic); clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); neu differentiation factor; pancreatic ductal carcinoma; kras gene; cdkn2a gene; brca2 gene; homologous recombination repair; chek2 gene; tp53 gene; immune checkpoint blockade; rad51 gene; tocilizumab; dabrafenib; trametinib; palb2 gene; smad4 gene; nivolumab; niraparib; rucaparib; recombination repair; humans; human; whole genome sequencing; binimetinib; pembrolizumab; durvalumab; whole exome sequencing; encorafenib; entrectinib; ecog performance status; larotrectinib; tumor mutational burden; high throughput technology; sotorasib; adagrasib; poly-adp ribose polymerase inhibitor; chk1 gene; mat2a gene; prmt5 gene; sos1 gene |
| Journal Title: | Expert Review of Gastroenterology and Hepatology |
| Volume: | 18 |
| Issue: | 1-3 |
| ISSN: | 1747-4124 |
| Publisher: | Informa Healthcare |
| Date Published: | 2024-01-01 |
| Start Page: | 55 |
| End Page: | 72 |
| Language: | English |
| DOI: | 10.1080/17474124.2024.2322648 |
| PUBMED: | 38415709 |
| PROVIDER: | scopus |
| PMCID: | PMC10960610 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work